Skip to main content
Top
Published in: Radiation Oncology 1/2017

Open Access 01-12-2017 | Short report

Novel three-dimensional bone ‘mapping’ software can help assess progression of osseous metastases from routine CT

Authors: D. Thurtle, G. M. Treece, T. Barrett, V. J. Gnanapragasam

Published in: Radiation Oncology | Issue 1/2017

Login to get access

Abstract

Imaging of bone metastasis response to therapy is a research priority. Stradwin is a new software-tool, with demonstrated sub-voxel accuracy in assessing cortical bone properties from routine CT. We applied this technology to the context of osseous metastases, with particular focus on disease progression using prostate cancer as a model. 3D–rendered ‘bone-maps’ were produced for 20 men with advanced prostate cancer, including a sub-cohort of 9 who had undergone serial scans. Correlation between baseline interpretation and assessments of progression between modalities was assessed. Bone-maps took significantly less time to interpret than CT bone windows (P < 0.001). Initial bone-mapping, without adjustment, demonstrated sensitivity and specificity for suspicious areas on CT of 70.7% and 73.1% respectively. Evaluating disease over time, concordance between bone-maps and current practice using RECIST outcomes was 100%.
This study demonstrates the feasibility and potential use of this free post-processing software in the serial assessment of osseous metastases.
Appendix
Available only for authorised users
Footnotes
1
Stradwin is available as a free download from http://​mi.​eng.​cam.​ac.​uk/​~rwp/​stradwin/​
 
Literature
1.
go back to reference Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47(2):287–97.PubMed Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47(2):287–97.PubMed
2.
go back to reference Thurtle D, Hsu RC, Chetan M, Lophatananon A, Hubbard R, Gnanapragasam VJ, et al. Incorporating multiparametric MRI staging and the new histological Grade Group system improves risk-stratified detection of bone metastasis in prostate cancer. Br J Cancer. 2016;115(11):1285–8.CrossRefPubMed Thurtle D, Hsu RC, Chetan M, Lophatananon A, Hubbard R, Gnanapragasam VJ, et al. Incorporating multiparametric MRI staging and the new histological Grade Group system improves risk-stratified detection of bone metastasis in prostate cancer. Br J Cancer. 2016;115(11):1285–8.CrossRefPubMed
3.
go back to reference Parker CC, Pascoe S, Chodacki A, O’Sullivan JM, Germá JR, O’Bryan-Tear CG, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63(2):189–97.CrossRefPubMed Parker CC, Pascoe S, Chodacki A, O’Sullivan JM, Germá JR, O’Bryan-Tear CG, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63(2):189–97.CrossRefPubMed
4.
go back to reference Lecouvet FE, Talbot JN, Messiou C, Bourguet P, Liu Y, de Souza NM, et al. Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer. 2014;50(15):2519–31.CrossRefPubMed Lecouvet FE, Talbot JN, Messiou C, Bourguet P, Liu Y, de Souza NM, et al. Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer. 2014;50(15):2519–31.CrossRefPubMed
5.
go back to reference Cook G, Parker C, Chua S, Johnson B, Aksnes AK, Lewington VJ. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res. 2011;1(1):4.CrossRefPubMedPubMedCentral Cook G, Parker C, Chua S, Johnson B, Aksnes AK, Lewington VJ. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res. 2011;1(1):4.CrossRefPubMedPubMedCentral
6.
go back to reference Treece GM, Gee AH, Mayhew PM, Poole KE. High resolution cortical bone thickness measurement from clinical CT data. Med Image Anal. 2010;14(3):276–90.CrossRefPubMedPubMedCentral Treece GM, Gee AH, Mayhew PM, Poole KE. High resolution cortical bone thickness measurement from clinical CT data. Med Image Anal. 2010;14(3):276–90.CrossRefPubMedPubMedCentral
7.
go back to reference Poole KE, Treece GM, Mayhew PM, Vaculík J, Dungl P, Horák M, et al. Cortical thickness mapping to identify focal osteoporosis in patients with hip fracture. PLoS One. 2012;7(6):e38466.CrossRefPubMedPubMedCentral Poole KE, Treece GM, Mayhew PM, Vaculík J, Dungl P, Horák M, et al. Cortical thickness mapping to identify focal osteoporosis in patients with hip fracture. PLoS One. 2012;7(6):e38466.CrossRefPubMedPubMedCentral
8.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed
Metadata
Title
Novel three-dimensional bone ‘mapping’ software can help assess progression of osseous metastases from routine CT
Authors
D. Thurtle
G. M. Treece
T. Barrett
V. J. Gnanapragasam
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2017
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-017-0880-2

Other articles of this Issue 1/2017

Radiation Oncology 1/2017 Go to the issue